

RWANDA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda					
2. Grant number: 1921-RWA-13b-X, 19-RWA-13b-A; 12-RWA-08a-Y					
3. Date of Decision Letter: 5 March 2019					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine					
6. Vaccine type: Rotavirus					
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 doses schedule					
8. Programme duration¹: 2012 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2012-2018	2019	2020	2021	Total ²
Programme Budget (US\$) (National)	25,802,611 ³	1,893,500	1,608,000	1,639,500	30,943,611
Programme Budget (US\$) (Refugee)	17,000	44,500	-	-	61,500
Total Programme Budget (US\$)	25,819,611	1,938,000	1,608,000	1,639,500	31,005,111
10. Vaccine introduction grant (in US\$): US\$ 126,500 disbursed on 30 January 2012					
11. Product switch grant: Not applicable					
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year (National)	2012-2018		2019		
Number of Rotavirus vaccines doses			816,000		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

Annual Amounts (US\$)	25,802,611 ⁵	1,893,500	
Type of supplies to be purchased with Gavi funds in each year (Refugee)	2012-2018	2019	
Number of Rotavirus vaccines doses		18,000	
Annual Amounts (US\$)	17,000	44,500	
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
14. Self-procurement: N/A			
<p>15. Co-financing obligations: Reference code: 1921-RWA-13b-X-C, 19-RWA-13b-A-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>			
Type of supplies to be purchased with Country funds in each year (National)	2019	2020	2021
Number of vaccine doses	78,000	66,000	67,500
Value of vaccine doses (US\$)	173,739	147,503	150,419
Total co-financing payments (US\$) (including freight)	179,000	152,000	155,000
Type of supplies to be purchased with Country funds in each year (Refugee)	2019	2020	2021
Number of vaccine doses	3,000	-	-
Value of vaccine doses (US\$)	4,082	-	-
Total co-financing payments (US\$) (including freight)	4,500	-	-
16. Operational support for campaigns: Not applicable			

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

17. Additional reporting requirements:	
	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
18. Financial clarifications: Not applicable	
19. Other conditions: Not applicable	

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019

RWANDA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda					
2. Grant number: 1921-RWA-04c-X, 19-RWA-04c-A					
3. Date of Decision Letter: 5 March 2019					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine					
6. Vaccine type: Pentavalent					
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 doses per vial, LIQUID					
8. Programme duration¹: 2002 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2002-2018	2019	2020	2021	Total ²
Programme Budget (US\$) (National)	46,865,848 ³	456,000	673,500	686,000	48,681,348
Programme Budget (US\$) (Refugee)	8,000	18,000	-	-	26,000
Total Programme Budget (US\$)	46,873,848	474,000	673,500	686,000	48,707,348
10. Vaccine introduction grant (in US\$): Not applicable					
11. Product switch grant: Not applicable					
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year (National)	2002-2018	2019			
Number of Pentavalent vaccines doses		640,500			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

Annual Amounts (US\$)	46,865,848 ⁵	456,000	
Type of supplies to be purchased with Gavi funds in each year (Refugee)	2015-2018	2019	
Number of Pentavalent vaccines doses		24,500	
Annual Amounts (US\$)	8,000	18,000	
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
14. Self-procurement: Not applicable			
<p>15. Co-financing obligations: Reference code: 1921-RWA-04c-X-C, 19-RWA-04c-A-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>			
Type of supplies to be purchased with Country funds in each year (National)	2019	2020	2021
Number of vaccine doses	251,000	370,500	377,500
Value of vaccine doses (US\$)	172,951	255,401	260,251
Total co-financing payments (US\$) (including freight)	178,500	263,500	268,500
Type of supplies to be purchased with Country funds in each year (Refugee)	2019	2020	2021
Number of vaccine doses	10,000	-	-
Value of vaccine doses (US\$)	6,693	-	-
Total co-financing payments (US\$) (including freight)	7,000	-	-
16. Operational support for campaigns: Not applicable			

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

17. Additional reporting requirements:	
	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
18. Financial clarifications: Not applicable	
19. Other conditions: Not applicable	

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019

RWANDA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda					
2. Grant number: 1921-RWA-12d-X, 19-RWA-12d-A; 08-RWA-08b-Y; 09-RWA-08c-Y; 17-RWA-25a-Y					
3. Date of Decision Letter: 5 March 2019					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 doses per vial , LIQUID					
8. Programme duration¹: 2009 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2009-2018	2019	2020	2021	Total ²
Programme Budget National (US\$)	35,298,992 ³	3,266,500	3,301,500	3,364,500	45,231,492
Programme Budget Refugee (US\$)	40,000	102,000	-	-	142,000
Total Programme Budget (US\$)	35,338,992	3,368,500	3,301,500	3,364,500	45,373,492
10. Vaccine introduction grant (in US\$): US\$ 117,000 disbursed on 6 August 2008 US\$ 422,650 disbursed on 20 February 2009					
11. Product switch grant: US\$ 87,707 disbursed on 31 August 2017					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year (National)	2009-2018	2019	
Number of Pneumococcal vaccines doses		971,600	
Annual Amounts (US\$)	35,298,992 ⁵	3,266,500	
Type of supplies to be purchased with Gavi funds in each year (Refugee)	2009-2018	2019	
Number of Pneumococcal vaccines doses		30,200	
Annual Amounts (US\$)	40,000	102,000	
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
14. Self-procurement: N/A			
<p>15. Co-financing obligations: Reference code: 1921-RWA-12d-X-C, 19-RWA-12-A-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>			
Type of supplies to be purchased with Country funds in each year (National)	2019	2020	2021
Number of vaccine doses	69,800	79,400	81,000
Value of vaccine doses (US\$)	205,756	234,089	238,554
Total co-financing payments (US\$) (including freight)	208,500	237,000	241,500
Type of supplies to be purchased with Country funds in each year (Refugee)	2019	2020	2021
Number of vaccine doses	2,200	-	-

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Value of vaccine doses (US\$)	6,402	-	-
Total co-financing payments (US\$) (including freight)	6,500	-	-
16. Operational support for campaigns: N/A			
17. Additional reporting requirements:			
		Due dates	
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 		<p>31 March 2019</p> <p>15 May 2019</p>	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Secretariat	
18. Financial clarifications: N/A			
19. Other conditions: N/A			

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019

RWANDA Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Rwanda					
2. Routine vaccines grant number: 1921-RWA-19b-X					
3. Date of Decision Letter: 5 March 2019					
4. Date of the Partnership Framework Agreement: 7 June 2013					
5. Programme title: New Vaccine Support (NVS), HPV Routine with multi age cohort in the year of introduction					
6. Vaccine type: HPV					
7. Requested product presentation and formulation of vaccine: <i>HPV Quadrivalent, 1 dose(s) per vial, LIQUID</i>					
8. Programme duration¹: 2014 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2014-2018	2019	2020	2021	Total ²
Programme Budget (Routine) (US\$)	7,331,034	976,500	1,176,500	1,200,000	10,684,034
10. Vaccine introduction grant (in US\$): Not applicable					
11. Operational support for Multi Age Cohort: Not applicable					
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³					
	Type of supplies to be purchased with Gavi funds in each year (Routine)	2014-2018	2019		
	Number of HPV vaccines doses		214,500		
	Annual Amounts (US\$)	7,331,034	976,500		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
14. Self-procurement: Not applicable					
15. Co-financing obligations: Reference code: 1921-RWA-19b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. ⁴					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

⁴ Co-Financing applies only to the routine cohort. (Multi age cohort is fully financed by Gavi)

Type of supplies to be purchased with Country funds each year	2019	2020	2021
Number of vaccine doses	9,900	11,900	12,200
Value of vaccine doses (US\$)	44,335	53,431	54,500
Total co-financing payments (US\$) (including freight)	45,000	54,500	55,500

16. Additional reporting requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi

Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

RWANDA Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number(s): 19-RWA-25c-X; 19-RWA-25c-A; 15-RWA-08h-Y			
3. Date of Decision Letter: 5 March 2019			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID			
8. Programme duration²: 2015 - 2019			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2018	2019	Total ³
Routine Programme (US\$) National	342,774 ⁴	1,056,500	1,399,274
Routine Programme (US\$) Refugees		30,000	30,000
10. Vaccine introduction grant: US\$ 338,000 disbursed on 5 March 2015			
11. Product switch grant: Not applicable			
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵			
Number of vaccines to be purchased with Gavi funds (National)	2015-2018	2019	
IPV Routine Programme (doses)		460,900	
Annual Amounts (US\$)	342,774	1,056,500	

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2019.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

Number of vaccines to be purchased with Gavi funds (Refugees)	2015-2018	2019
IPV Routine Programme (doses)		13,100
Annual Amounts (US\$)	342,774	30,000
13. Procurement agency: UNICEF		
14. Self-procurement: Not applicable		
15. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Rwanda is encouraged to contribute to vaccine and/or supply costs for IPV.		
16. Operational support for catch-up campaigns: Not applicable		
17. Additional reporting requirements:		
	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		
<ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019	
	15 May 2019	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
18. Financial clarifications: Not applicable		
19. Other conditions:		
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Rwanda envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Rwanda.</p>		

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

RWANDA Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 19-RWA-09a-X; 19-RWA-18e-A			
3. Date of Decision Letter: 5 March 2019			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), Measles-Rubella Second Dose routine (refugee), Measles-Rubella Strategy 1 (national)			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 doses per vial, LYOPHILISED			
8. Programme duration¹: 2015 - 2019			
9. Programme Budget (indicative) - national: (subject to the terms of the partnership framework agreement, if applicable)			
	2015-2018	2019	Total ²
Programme Budget - Routine (US\$)	555,942	119,000	674,942
Programme Budget (indicative) - refugee: (subject to the terms of the partnership framework agreement, if applicable)			
	2018	2019	Total ³
Programme Budget - Routine (US\$)	4,500	11,500	16,000
10. Indicative Annual Amounts - national: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year (Routine)	2015-2018	2019	
Number of Measles vaccines doses		382,200	
Annual Amounts (US\$)	555,942	119,000	
Indicative Annual Amounts - refugee: (subject to the terms of the Partnership Framework Agreement, if applicable)			
Type of supplies to be purchased with Gavi funds in each year (Routine)	2018	2019	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

	Number of Measles-Rubella vaccines doses		17,700										
	Annual Amounts (US\$)	4,500	11,500										
<p>11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>													
<p>12. Self-procurement: N/A</p>													
<p>13. Co-financing obligations for routine: Reference code: 19-RWA-18e-A-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1" data-bbox="290 707 1302 1088"> <tr> <td>Type of supplies to be purchased with Country funds in each year (refugee)</td> <td>2019</td> </tr> <tr> <td>Number of vaccine doses</td> <td>15,100</td> </tr> <tr> <td>Number of safety boxes</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$9,657</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$10,000</td> </tr> </table>				Type of supplies to be purchased with Country funds in each year (refugee)	2019	Number of vaccine doses	15,100	Number of safety boxes		Value of vaccine doses (US\$)	US\$9,657	Total co-financing payments (US\$) (including freight)	US\$10,000
Type of supplies to be purchased with Country funds in each year (refugee)	2019												
Number of vaccine doses	15,100												
Number of safety boxes													
Value of vaccine doses (US\$)	US\$9,657												
Total co-financing payments (US\$) (including freight)	US\$10,000												
<p>14. Co-financing obligations for campaign: N/A</p>													
<p>15. Vaccine introduction grant (in US\$): N/A</p>													
<p>16. Operational support for campaigns: N/A</p>													
<p>17. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:</p> <table border="1" data-bbox="209 1400 1294 1939"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2019 15 May 2019 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>					Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat				
	Due dates												
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019												
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat												
<p>18. Financial clarifications: N/A</p>													

Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2019
Number of doses of vaccines for Measles Second Dose approved by Gavi.	382,200
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	116,953
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	182,739
Number of doses of Measles-Rubella vaccine to be funded by country.	199,461
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	127,655

In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
5 March 2019